Cordycepin Clears Brain Protein Clumps Tied to Parkinson's Earliest Symptom

Parkinson's disease (PD) is typically diagnosed after significant neurodegeneration has already occurred. Olfactory dysfunction — loss of smell — is among the earliest warning signs, often appearing years before tremor or rigidity. Targeting this prodromal window could be transformative for disease modification, yet most experimental therapies focus on motor symptoms.

This study examined whether cordycepin (Cor), an adenosine analogue derived from Cordyceps fungi with known anti-inflammatory and antioxidant properties, could intervene at PD's earliest stage. Researchers treated rotenone-exposed mice (a standard PD model) beginning at eight weeks of age — before motor deficits emerged — and tracked olfactory and motor outcomes alongside molecular changes in the olfactory bulb (OB).

Cordycepin significantly improved olfactory function and delayed motor impairment onset. RNA sequencing of OB tissue implicated the autophagy-lysosomal pathway (ALP) as a central mechanism. In rotenone-treated SH-SY5Y neuronal cells, cordycepin stabilized CacyBP/SIP protein by blocking its ubiquitin-proteasome degradation. This stabilization suppressed NLRP3 inflammasome activation and enhanced autophagosome-lysosome fusion, enabling more efficient degradation of pathological α-synuclein aggregates. Blocking CacyBP/SIP eliminated cordycepin's protective effects, confirming its mechanistic centrality.

The findings define a CacyBP/SIP–NLRP3–α-synuclein axis as a novel therapeutic target and position cordycepin as a candidate disease-modifying agent rather than merely symptomatic relief.

Key caveats include reliance on a single rodent model (rotenone) and cell line, an all-male mouse cohort limiting generalizability, and the absence of human or clinical data. Translation to PD patients requires pharmacokinetic studies and trials.